Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

Baas, H.; Beiske, A. G.; Ghika, J.; Jackson, M.; Oertel, W. H.; Poewe, W.; Ransmayr, G.
October 1997
Journal of Neurology, Neurosurgery & Psychiatry;Oct1997, Vol. 63 Issue 4, p421
Academic Journal
No abstract available.


Related Articles

  • Tolcapone: a review of its use in the management of Parkinson's disease. Keating, Gillian M.; Lyseng-Williamson, Katherine A. // CNS Drugs;2005, Vol. 19 Issue 2, p165 

    Tolcapone (Tasmar) is a selective, reversible inhibitor of peripheral and central catechol-O-methyltransferase (COMT). Results of well designed studies indicate that oral tolcapone is an effective adjunct to levodopa plus a peripheral dopa-decarboxylase inhibitor (DDCI) in patients with...

  • Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease. Kaakkola, S. // Drugs;Jun2000, Vol. 59 Issue 6, p1233 

    When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have...

  • Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease. Baas, H.; Zehrden, F.; Selzer, R.; Kohnen, R.; Loetsch, J.; Harder, S. // Clinical Pharmacokinetics;2001, Vol. 40 Issue 5, p383 

    Objective: To investigate the effect of administration of the catechol-Omethyltransferase (COMT) inhibitor tolcapone on the concentration-effect relationship of levodopa in patients with advanced Parkinson's disease and on-off fluctuations.Design: Nonblind single-group...

  • Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol- O-methyltransferase inhibition. Muhlack, Siegfried; Herrmann, Lennard; Salmen, Stephan; Müller, Thomas // Journal of Neural Transmission;Nov2014, Vol. 121 Issue 11, p1357 

    Catechol- O-methyltransferase inhibitor addition to levodopa/carbidopa formulations improves motor symptoms and reduces levodopa fluctuations in patients with Parkinson's disease. Objectives were to investigate the effects of entacapone and tolcapone on plasma behaviour of levodopa, its...

  • Tolcapone is worth a try when other treatments in patients with fluctuating Parkinson's disease fail or are inappropriate. Adis International Limited // Drugs & Therapy Perspectives;Nov2005, Vol. 21 Issue 11, p1 

    Looks at the role of tolcapone in the treatment of patients with fluctuating Parkinson's disease. Discussion of the efficacy of levodopa with regards to the treatment; Effect of tolcapone on levodopa-induced fluctuations; Comparison of the efficacy of tolcapone with that of entacapone.

  • Abdominal Pain: A Symptom of Levodopa End of Dose Wearing off in Parkinson's Disease. Rana, A. Q.; Depradine, J. // West Indian Medical Journal;Mar2011, Vol. 60 Issue 2, p223 

    Long-term levodopa use is associated with the "End of Dose Wearing Off" (EODWO) phenomenon wherein Parkinsonian symptoms return before a patient's next scheduled dose of levodopa. Wearing off symptoms may include a variety of autonomic, emotional, motor, psychological and sensory abnormalities....

  • Motor fluctuations in Parkinson's disease. Kikuchi, Seiji // Journal of Neurology;Sep2007, Vol. 254 Issue S5, p32 

    Almost all patients with Parkinson's disease will eventually require levodopa during the course of their disease. The effectiveness of levodopa is evident, but earlier use and higher doses are causative of the emergence of motor fluctuations. About one half of patients develop motor fluctuations...

  • Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson's Disease. Jankovic, Joseph; Stacy, Mark // CNS Drugs;2007, Vol. 21 Issue 8, p677 

    Parkinson's disease is a neurodegenerative disorder that affects approximately 1% of people over the age of 60 years. Levodopa is standard, and often initial, therapy for patients with this condition; however, with continued treatment and as the disease progresses, up to 80% of patients...

  • Comparative Tolerability of the Newer Generation Antiparkinsonian Agents. Lambert, D.; Waters, C.H. // Drugs & Aging;2000, Vol. 16 Issue 1, p55 

    In recent years, the treatment of Parkinson's disease has undergone an immense amount of research, resulting in the development of multiple new medications. This has largely been fuelled by dissatisfaction over the development of motor complications secondary to long term levodopa therapy....

  • Treating and Preventing Levodopa-Induced Dyskinesias: Current and Future Strategies. Durif, F. // Drugs & Aging;1999, Vol. 14 Issue 5, p337 

    Prevention of levodopa-induced dyskinesias is a therapeutic challenge for physicians. At present, it seems only possible to delay dyskinesias and motor fluctuations. In younger patients (aged <50 years), the strategy is to use a dopamine D agonist as monotherapy and then to add levodopa...


Read the Article


Sign out of this library

Other Topics